Decent trading update found here..

http://www.companyannouncements.net/cgi-bin/articles/200601090700205996W.html

Marketing of Vetoryl capsules in Europe to begin before the end of June, and a regulatory aplication package intended to be submitted in late 2007. Group revenue growth at 11% amidst increased product development expenditure.

In summary, expansion remains as planned and the cashflow generation and evaluation of DPH are supportive of further increases in the SP as revenue flows (hopefully) start to 'kick in' in future years, IMHO.